RGTA2 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
14-16 week lead time (made-to-order)
Synonyms
RGTA2 antibody; At5g41820 antibody; K16L22.10Geranylgeranyl transferase type-2 subunit alpha 2 antibody; EC 2.5.1.60 antibody; Geranylgeranyl transferase type II subunit alpha 2 antibody; Rab geranylgeranyl transferase alpha subunit 2 antibody; AtRGTA2 antibody; Rab-GGT alpha 2 antibody
Target Names
RGTA2
Uniprot No.

Target Background

Function
This antibody targets RGTA2, which catalyzes the geranylgeranyl moiety transfer from geranylgeranyl diphosphate to the cysteine residues within the C-terminal -CCXX, -CXXX, -XCCX, and -XCXC sequences of Rab proteins, including RABA1A, RABA2A, RABF2A, and RABG2. In vitro studies suggest RGTA2 may not function as a typical Rab geranylgeranyl transferase alpha subunit.
Database Links
Protein Families
Protein prenyltransferase subunit alpha family

Q&A

FAQs for Researchers: TRA2B Antibody (Transformer 2 Beta Homolog)

Advanced Research Questions

  • What experimental design considerations are critical for validating TRA2B antibodies in RA cohorts?

    • Cohort Splitting: Use training and validation cohorts (e.g., 80:20 split) to avoid overfitting. The German study used n = 329 (training) and n = 82 (validation) .

    • Multiplex Assays: Prioritize high-throughput platforms to screen large antigen panels (e.g., 390 proteins) .

    • Statistical Rigor: Apply Bonferroni-Holm correction for multiple testing and GLM for multivariable analysis .

  • How can researchers resolve contradictions in TRA2B antibody data across studies?

    • Cross-Validation: Replicate findings in independent cohorts (e.g., validation cohort sensitivity: 39.5% vs. training cohort: 51.0%) .

    • Antigen Specificity: Confirm citrullination status via mass spectrometry or enzymatic assays, as TRA2B contains 64 arginine residues prone to modification .

    • Contextual Factors: Account for comorbidities (e.g., cancer, where TRA2B is a survival factor) that may confound antibody reactivity .

  • What methodologies improve the integration of TRA2B antibodies into diagnostic frameworks?

    • Combination Scores: Develop composite scores (e.g., ACPA + cTRA2B + RF) to enhance diagnostic accuracy. A score ≥2 achieved 43.4% sensitivity and 94.1% specificity .

    • Longitudinal Tracking: Monitor antibody titers pre/post-treatment (e.g., methotrexate or biologics) to assess prognostic value .

Data Tables

Table 1: Diagnostic Performance of TRA2B Antibodies in Early RA

CohortSensitivity (%)Specificity (%)AUC (95% CI)
Training51.082.90.71 (0.63–0.79)
Validation39.584.20.68 (0.58–0.78)
Adapted from ROC analysis in .

Table 2: Key Challenges in TRA2B Antibody Research

ChallengeMitigation Strategy
Low sensitivity vs. ACPACombine with ACPA/RF (p = 0.026)
Antigen cross-reactivityUse in vitro citrullinated antigens
Interference from RFPre-treat sera with RF absorbents

Methodological Recommendations

  • Antibody Validation: Use CiteAb (citeab.com) to identify TRA2B antibodies with peer-reviewed citations, ensuring reproducibility .

  • Data Interpretation: Address RF interference in immunoassays via linear regression adjusting for RF IgA/IgM .

  • Public Antibody Databases: Leverage repositories like the SARS-CoV-2 antibody dataset for comparative structural analyses.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.